Beam Therapeutics Publishes BEACON Phase 1/2 Data For Risto-Cel In Patients With Sickle Cell Disease In The New England Journal of Medicine; U.S. Biologics License Application Submission for Risto-Cel Expected As Early As Year-End 2026

Beam Therapeutics has published data from its Phase 1/2 BEACON clinical trial for ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) in The New England Journal of Medicine. The trial involved 31 patients and showed significant improvements in red blood cell dysfunction and reduced hospital time, with a median of one cell collection cycle and rapid engraftment. The company expects to submit a U.S. Biologics License Application for risto-cel as early as year-end 2026.